PJ34 - CAS# 344458-19-1 e O-desmethyl Mebeverine acid CNX-1351 potently inhibited PI3Kα and

CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β

1 fmole/nucleus of methylproamine is required to achieve a substantial level of radioprotection (DMF of 1

NSC59984 as a promising lead compound for anticancer therapy that acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling

Surapaneni S

Ennaceur A

PJ34 - CAS# 344458-19-1 e O-desmethyl Mebeverine acid CNX-1351 potently inhibited PI3Kα andPJ 34 is a novel and potent PARP 1 inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP 1 (IC(50) = 20 nM). PJ 34 inhibits PARP 1 expression and ERK phosphorylation in glioma conditioned brain microvascular endothelial cells. PJ 34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. PJ 34 reduce cell inflammation and damage that follow PARP 1 overexpression. PJ 34 negatively